Clareo Health | Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation
Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Women and men with diagnosis of chronic obstructive pulmonary disease (COPD) with a thoracic gas volume (TGV) \> = 120% as measured by body plethysmography
Only patients who have not yet been treated with Spiriva® 18 micrograms can be included in the study.
You may not be if
Patients who presenting the general and specific contraindications mentioned in the Patient Information and Prescribing Information
